The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Ultraproct 0.92mg/g + 0.95mg/g + 5mg/g Rectal Ointment

Karo Pharma ABPA22650/004/001

Main Information

Trade NameUltraproct 0.92mg/g + 0.95mg/g + 5mg/g Rectal Ointment
Fluocortolone caproate
Cinchocaine Hydrochloride
Dosage FormRectal ointment
Licence HolderKaro Pharma AB
Licence NumberPA22650/004/001

Group Information

ATC CodeC05AA Corticosteroids
C05AA08 fluocortolone


License statusAuthorised
Licence Issued01/04/1978
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back